Follow the entities shaping the evidence.

… a 8.3 month increase in median overall survival when receiving ICI+C versus ICI alone, whereas patients with a low score (∆TRI ≤16, …

…p<0.001 (n=3)Abstract 359 Figure 2Tumor-trained splenocytes reg melanoma growth. (A) Low burden: B16 (1×104) + trained splenocytes (1×10…

… cells from the tumor and spleen in the MC38 model treated with INCB177054 ± anti-PD1 using paired scRNA-seq and single cell T-cell recept…

…S and suppression of the cGAS-STING axis. Targeting CHCHD3 with TN4510 restores antitumor immunity and enhances neoadjuvant therapy ef…

…ons This FIH study of the novel anti-ROR1 monocloncal antibody, PBA-0405, illustrates the potential of this drug to induce immune cell m…

…histology-specific platinum doublet chemotherapy, combined with ipilimumab (1 mg/kg every 6 weeks) and nivolumab (360 mg every 3 weeks), f…

…s and peripheral blood T-cell responses are ongoing.Conclusions DOC1021 immunotherapy after surgical resection and standard neoadjuvant…

…n by metabolic stress, immunosuppression, and T cell exhaustion.IB-T101, an autologous CAR-T targeting CD70 in ccRCC, is expanded under…

…g Ki-67, PD-1, CD25, HLA-DR, CD137, TIM-3 and LAG-3.Conclusions ISB 2001 demonstrated dose proportional PK, a high ORR and acceptable sa…

…K), pharmacodynamics (PD), and preliminary clinical activity of ES009.Methods This open-label, multicenter, non-randomized Phase 1 st…

…ond or progress on CI treatment. Clinical data demonstrate that AdAPT-001 induces a tumor-specific inflammatory response, reverses the tu…

…Background Acute myeloid leukemia (AML) accounts for 25% of acute leukemias in children and 33% i…